DCM
DNLI icon

DAFNA Capital Management’s Denali Therapeutics DNLI Stock Holding History

DAFNA Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19M Buy
739,014
+420,514
+132% +$8.64M 3.62% 6
2026
Q1 		$6.12M Hold
318,500
– – 1.39% 19
2025
Q4 		$5.26M Buy
318,500
+150,000
+89% +$2.53M 1.22% 22
2025
Q3 		$2.45M Hold
168,500
– – 0.6% 38
2025
Q2 		$2.36M Buy
168,500
+40,600
+32% +$571K 0.65% 35
2025
Q1 		$1.74M Buy
+127,900
New +$2.45M 0.49% 41

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DAFNA Capital Management's DNLI Position: Q2 2026 in Review

DAFNA Capital Management increased its Denali Therapeutics (DNLI) stake by 132% in Q2 2026, buying an estimated $8.64M and bringing the position to 739,014 shares worth $19M. The position accounts for 3.62% of the portfolio, ranked #6.

DAFNA Capital Management first reported a position in DNLI in Q1 2025 and has held it in 6 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • DAFNA Capital Management held 739,014 shares of Denali Therapeutics worth $19M as of Q2 2026.
  • DAFNA Capital Management bought 420,514 Denali Therapeutics shares in Q2 2026, an estimated $8.64M.
  • Denali Therapeutics made up 3.62% of DAFNA Capital Management's portfolio in Q2 2026, its #6 holding.
  • DAFNA Capital Management first reported a position in Denali Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on DAFNA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.